Concepedia

John R. Eckardt

JR

55

Publications

3.5K

Citations

33

H-Index

1993

Active since

Affiliations

The University of Texas Health Science Center at San Antonio(Current)

Brooke Army Medical Center

Joint Base San Antonio

St. John's University

Arog Pharmaceuticals (United States)

John R. Eckardt is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

1993–2017

55

Publications

55

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Jean-Louis Pujol et al. · Journal of Clinical Oncology · 2007 · 380 citations

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Mace L. Rothenberg, John R. Eckardt, John G. Kuhn et al. · Journal of Clinical Oncology · 1996 · 351 citations

Phase I and pharmacokinetic trial of weekly CPT-11.

Mace L. Rothenberg, John G. Kuhn, Howard A. Burris et al. · Journal of Clinical Oncology · 1993 · 301 citations

, , +13

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

David Rinaldi, Howard A. Burris, F. Andrew Dorr et al. · Journal of Clinical Oncology · 1995 · 152 citations

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Zsolt Pápai et al. · Journal of Clinical Oncology · 2006 · 146 citations · Full text

Rows per page

1–5 of 55